263 related articles for article (PubMed ID: 28133105)
1. [Two Cases of Metastatic Rectal Cancer Patients Who Received Chemotherapy with FOLFOXIRI plus Bevacizumab].
Nishii T; Uchima Y; Yamakoshi Y; Wang E; Nagashima D; Hirakawa T; Aomatsu N; Iwauchi T; Morimoto J; Nakazawa K; Tei S; Takeuchi K
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1705-1707. PubMed ID: 28133105
[TBL] [Abstract][Full Text] [Related]
2. [A Case of a Patient with Locally Recurrent Rectal Cancer Who Underwent Surgical Resection after Chemotherapy with FOLFOXIRI plus Bevacizumab].
Shigoka M; Enomoto M; Wada T; Mazaki J; Kuwabara H; Ishizaki T; Ishibashi Y; Nagakawa Y; Katsumata K; Tsuchida A
Gan To Kagaku Ryoho; 2019 Apr; 46(4):796-798. PubMed ID: 31164539
[TBL] [Abstract][Full Text] [Related]
3. FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.
Tomasello G; Petrelli F; Ghidini M; Russo A; Passalacqua R; Barni S
JAMA Oncol; 2017 Jul; 3(7):e170278. PubMed ID: 28542671
[TBL] [Abstract][Full Text] [Related]
4. [Pathological Complete Response in a Case of Multiple Liver Metastases from Rectal Cancer Treated with XELOX plus Bevacizumab(Bev)Therapy].
Noura S; Shuto T; Muratsu A; Yoshida Y; Yasuyama A; Matsumura T; Koga C; Kameda C; Murakami M; Kawabata R; Hirota M; Yoshikawa M; Shimizu J; Hasegawa J; Miwa H
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1742-1744. PubMed ID: 28133117
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
[TBL] [Abstract][Full Text] [Related]
6. [A Long-Survival Case of Lower Rectal Cancer with Unresectable Liver Metastases Treated with FOLFOXIRI plus Bevacizumab(BEV)].
Kagawa Y; Inoue A; Nishizawa Y; Kawai K; Ohta T; Hata T; Naito A; Komatsu H; Miyazaki Y; Tomokuni A; Motoori M; Fujitani K; Kato T; Takeda Y; Murata K
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1819-1821. PubMed ID: 35046341
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Cremolini C; Casagrande M; Loupakis F; Aprile G; Bergamo F; Masi G; Moretto R R; Pietrantonio F; Marmorino F; Zucchelli G; Tomasello G; Tonini G; Allegrini G; Granetto C; Ferrari L; Urbani L; Cillo U; Pilati P; Sensi E; Pellegrinelli A; Milione M; Fontanini G; Falcone A
Eur J Cancer; 2017 Mar; 73():74-84. PubMed ID: 27986363
[TBL] [Abstract][Full Text] [Related]
8. Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
Fornaro L; Vasile E; Masi G; Loupakis F; Baldi GG; Allegrini G; Salvatore L; Cremolini C; Cupini S; Cortesi E; Tuzi A; Granetto C; Brunetti IM; Ricci S; Falcone A
Clin Colorectal Cancer; 2012 Mar; 11(1):71-6. PubMed ID: 21903485
[TBL] [Abstract][Full Text] [Related]
9. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.
Masi G; Vivaldi C; Fornaro L; Lonardi S; Buccianti P; Sainato A; Marcucci L; Martignetti A; Luca Urso ED; Castagna M; Fontanini G; Bergamo F; Musettini G; Urbani L; Sensi E; Balestri R; Montrone S; Pasqualetti F; Cremolini C; Di Paolo A; Zagonel V; Falcone A
Eur J Cancer; 2019 Mar; 110():32-41. PubMed ID: 30739838
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
[TBL] [Abstract][Full Text] [Related]
11. [A Case of Rectal Cancer with Multiple Liver, Lung, and Para-Aortic Lymph Node Metastases Successfully Treated with FOLFOX4 plus Bevacizumab].
Takahashi S; Hanaka J; Takahashi M; Kanamura S; Wakamatsu T; Nakayama H; Goya T
Gan To Kagaku Ryoho; 2015 Dec; 42(13):2489-91. PubMed ID: 26809311
[TBL] [Abstract][Full Text] [Related]
12. [A case with liver resection of metastasis from rectal cancer after FOLFOX4+bevacizumab treatment].
Kojima T; Matsui T; Uemura T; Fujimitsu Y; Kure N; Kojima H
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1761-3. PubMed ID: 18931584
[TBL] [Abstract][Full Text] [Related]
13. [Two Cases of Advanced Colorectal Cancer Achieving Complete Response by FOLFOXIRI plus Bevacizumab-A Case Report].
Nemoto T; Endo S; Isohata N; Takayanagi D; Nemoto D; Aizawa M; Utano K; Togashi K; Oshibe I; Soeta N; Saito T
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2410-2412. PubMed ID: 32156948
[TBL] [Abstract][Full Text] [Related]
14. [A Case Report on a Successful Resection after FOLFIRI plus Cetuximab Therapy for Unresectable Colorectal Cancer with Multiple Liver Metastases].
Kanamori M; Kurumiya Y; Mizuno K; Sekoguchi E; Kobayashi S; Fukami Y; Kiriyama M; Aoyama H; Oiwa T; Miyamura K; Jinno T; Nakashima Y; Mori M
Gan To Kagaku Ryoho; 2017 May; 44(5):417-420. PubMed ID: 28536339
[TBL] [Abstract][Full Text] [Related]
15. [A Case of Chemotherapy with FOLFOXIRI plus Cetuximab for Liver Metastasis of Sigmoid Colon Cancer].
Saito A; Konishi K; Fukunaga M; Takiguchi N; Nakai S; Honda S; Yukimoto R; Okamoto A; Takeoka T; Matsuno H; Okada K; Ota H; Yokoyama S; Konishi M; Kobayashi K
Gan To Kagaku Ryoho; 2018 Mar; 45(3):507-509. PubMed ID: 29650920
[TBL] [Abstract][Full Text] [Related]
16. [A case with liver resection of metastasis from rectal cancer after bevacizumab treatment].
Nishida K; Matsuyama T; Masuda D; Hosokawa T; Tokita H; Kakimoto M; Goto H; Yoshimura T; Koshiishi H; Okamura T
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2517-9. PubMed ID: 21224625
[TBL] [Abstract][Full Text] [Related]
17. Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer.
Naiken SP; Toso C; Rubbia-Brandt L; Thomopoulos T; Roth A; Mentha G; Morel P; Gervaz P
BMC Surg; 2014 Jan; 14():4. PubMed ID: 24438090
[TBL] [Abstract][Full Text] [Related]
18. [Two Episodes of Colostomy-Associated Intestinal Perforation during Chemotherapy for Metastatic Rectal Cancer].
Tamura H; Otani A; Tsukui M; Toge K; Otani T; Hirose Y; Morimoto Y; Yoshino K; Kido T; Endo K; Kameyama H; Kobayashi T; Wakai T
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2172-2174. PubMed ID: 28133259
[TBL] [Abstract][Full Text] [Related]
19. Successful resection of metachronous para-aortic, Virchow lymph node and liver metastatic recurrence of rectal cancer.
Takeshita N; Fukunaga T; Kimura M; Sugamoto Y; Tasaki K; Hoshino I; Ota T; Maruyama T; Tamachi T; Hosokawa T; Asai Y; Matsubara H
World J Gastroenterol; 2015 Nov; 21(44):12722-8. PubMed ID: 26640350
[TBL] [Abstract][Full Text] [Related]
20. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
